<?xml version="1.0" encoding="utf-8"?>
<rss 
  version="2.0">
  <channel xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/">
    <title>BriaCell Therapeutics Corp.</title>
    <link>https://www.globenewswire.com/rssfeed/organization/Nshlon6Jkf3bXvk_Rk96TA==</link>
    <description>Contains the last 20 releases</description>
    <copyright>Copyright 2024, BriaCell Therapeutics Corp.</copyright>
    <managingEditor>newsdesk@globenewswire.com (NewsDesk)</managingEditor>
    <lastBuildDate>Mon, 02 Dec 2024 12:50:00 GMT</lastBuildDate>
    <webMaster>webmaster@globenewswire.com (Webmaster)</webMaster>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/12/02/2989718/0/en/BriaCell-Receives-Green-Light-from-Data-Safety-Monitoring-Board-for-its-Phase-3-Study-in-Metastatic-Breast-Cancer.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/12/02/2989718/0/en/BriaCell-Receives-Green-Light-from-Data-Safety-Monitoring-Board-for-its-Phase-3-Study-in-Metastatic-Breast-Cancer.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX:BCT</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:BCTXW</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:BCTX</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA10778Y1043</category>
      <title>BriaCell Receives Green-Light from Data Safety Monitoring Board for its Phase 3 Study in Metastatic Breast Cancer</title>
      <description><![CDATA[<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, Dec.  02, 2024  (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Data Safety Monitoring Board (DSMB), an independent group of experts who review and monitor safety data of a clinical study to determine if a study should continue, be modified, or be halted early, has completed its first review of safety events in patients enrolled in BriaCell’s pivotal randomized Phase 3 study of Bria-IMT™ plus an immune checkpoint inhibitor (CPI) combination regimen (<a href="https://www.globenewswire.com/Tracker?data=E5S4X3_2OyWCaze59pAWD4iTKlZkuDIwNsoo1BXzqyOmDgP0YVVxoQiXjrsfiAg5z8crUzf9VeZUhtaZUvS_rA2gwxDT0V0nyHt8XK4ZdlA=" rel="nofollow" target="_blank" title="NCT06072612">NCT06072612</a>). The DSMB issued a statement recommending continuation of the study in metastatic breast cancer patients. BriaCell’s pivotal Phase 3 study is currently being conducted under Fast Track Designation with the Food and Drug Administration (FDA).</p>]]></description>
      <pubDate>Mon, 02 Dec 2024 12:50 GMT</pubDate>
      <dc:identifier>2989718</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>BriaCell Therapeutics Corp.</dc:contributor>
      <dc:modified>Mon, 02 Dec 2024 12:50 GMT</dc:modified>
      <dc:subject>Health</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/11/26/2987415/0/en/BriaCell-2024-SABCS-Spotlight-Poster-to-Showcase-Positive-Overall-Survival-Data-Across-All-Patient-Subtypes-in-Metastatic-Breast-Cancer.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/11/26/2987415/0/en/BriaCell-2024-SABCS-Spotlight-Poster-to-Showcase-Positive-Overall-Survival-Data-Across-All-Patient-Subtypes-in-Metastatic-Breast-Cancer.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX:BCT</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:BCTXW</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:BCTX</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA10778Y1043</category>
      <title>BriaCell 2024 SABCS® Spotlight Poster to Showcase Positive Overall Survival Data Across All Patient Subtypes in Metastatic Breast Cancer</title>
      <description><![CDATA[<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, Nov.  26, 2024  (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, will be highlighting its positive overall survival and clinical benefit data in metastatic breast cancer (MBC) patients including those with CNS metastasis (not shown on the abstracts) who were treated with the Bria-IMT™ plus immune checkpoint inhibitor (CPI) combination in its “Spotlight” poster presentation session, at the 2024 San Antonio Breast Cancer Symposium<sup>®</sup> (SABCS<sup>®</sup>) held at Henry B. Gonzalez Convention Center, San Antonio, TX.</p>]]></description>
      <pubDate>Tue, 26 Nov 2024 12:50 GMT</pubDate>
      <dc:identifier>2987415</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>BriaCell Therapeutics Corp.</dc:contributor>
      <dc:modified>Tue, 26 Nov 2024 12:50 GMT</dc:modified>
      <dc:subject>Calendar of Events</dc:subject>
      <dc:subject>Health</dc:subject>
      <dc:subject>Clinical Study</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/11/25/2986614/0/en/BriaCell-Provides-Update-to-its-Board-of-Directors.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/11/25/2986614/0/en/BriaCell-Provides-Update-to-its-Board-of-Directors.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX:BCT</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:BCTXW</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:BCTX</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA10778Y1043</category>
      <title>BriaCell Provides Update to its Board of Directors</title>
      <description><![CDATA[<p align="justify">PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Nov.  25, 2024  (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that it has accepted the resignation of Mr. Marc Lustig, MSc, MBA from the Board of Directors, effective immediately. The Board thanks Marc for his strong contributions to the Company over his tenure.</p>]]></description>
      <pubDate>Mon, 25 Nov 2024 12:50 GMT</pubDate>
      <dc:identifier>2986614</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>BriaCell Therapeutics Corp.</dc:contributor>
      <dc:modified>Mon, 25 Nov 2024 12:50 GMT</dc:modified>
      <dc:subject>Directors and Officers</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/11/21/2985129/0/en/BriaCell-Announces-First-Patient-Dosed-with-Bria-OTS-in-Metastatic-Breast-Cancer-Study.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/11/21/2985129/0/en/BriaCell-Announces-First-Patient-Dosed-with-Bria-OTS-in-Metastatic-Breast-Cancer-Study.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX:BCT</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:BCTXW</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:BCTX</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA10778Y1043</category>
      <title>BriaCell Announces First Patient Dosed with Bria-OTS™ in Metastatic Breast Cancer Study</title>
      <description><![CDATA[<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, Nov.  21, 2024  (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) a clinical-stage biotech company that develops novel immunotherapies to transform cancer care, announces that the first patient was dosed in its Phase 1/2 study (ClinicalTrials.gov identifier: <a href="https://www.globenewswire.com/Tracker?data=KNgzR3SBqziAthOjkEmHdvBqqazDFmegivZm67j44DBDmABUeahOhTY3zZyrycEjE9BEt3x9jM3XJBwS8hx6J564dVRr4UfRV4gKjHBrpeizgZk5fQpq73iCLLL_e0FxYMW809TxOr7k2uzCFbvYLA==" rel="nofollow" target="_blank" title="NCT06471673">NCT06471673</a>) to evaluate the safety and efficacy of Bria-OTS™, BriaCell’s personalized next generation immunotherapy. The study will investigate Bria-OTS™ alone and in combination with immune check point inhibitor tislelizumab<sup>®</sup> (manufactured and <a href="https://www.globenewswire.com/Tracker?data=oppHSXdMEOaP6c8HQrB3rTJViD9FPgVD541iF6W8qmb8Fli1aRPr7zC7hlOqVFskzElg6FRUU6DojzLcetA1NlJxShgbt5Vgm-NUdhDrTcS-2-W8S0Ed8GgSZdhnRWl0k3MBWBAvM1dagc_i2tqLBmkQGwH_XakJ1TOBXiKtfbo=" rel="nofollow" target="_blank" title="supplied by BeiGene, Ltd.">supplied by BeiGene, Ltd.</a>) for the treatment of metastatic breast cancer. Bria-OTS™ is an enhanced form of Bria-IMT™, currently in pivotal Phase 3 study for metastatic breast cancer.</p>]]></description>
      <pubDate>Thu, 21 Nov 2024 12:50 GMT</pubDate>
      <dc:identifier>2985129</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>BriaCell Therapeutics Corp.</dc:contributor>
      <dc:modified>Thu, 21 Nov 2024 12:50 GMT</dc:modified>
      <dc:subject>Health</dc:subject>
      <dc:subject>Product / Services Announcement</dc:subject>
      <dc:subject>Clinical Study</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/11/08/2977589/0/en/BriaCell-Showcases-Robust-Anti-Cancer-Activity-of-Personalized-Off-the-Shelf-Immunotherapy-Pipeline-at-the-2024-SITC-Conference.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/11/08/2977589/0/en/BriaCell-Showcases-Robust-Anti-Cancer-Activity-of-Personalized-Off-the-Shelf-Immunotherapy-Pipeline-at-the-2024-SITC-Conference.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX:BCT</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:BCTXW</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:BCTX</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA10778Y1043</category>
      <title>BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference</title>
      <description><![CDATA[<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, Nov.  08, 2024  (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today is pleased to report preclinical data showing strong anti-cancer activity of its next generation, personalized, off-the-shelf, cell-based breast and prostate cancer immunotherapies, Bria-BRES+™ and Bria-PROS+™, respectively, during a poster session at the 2024 Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, held November 6-10, 2024, in Houston, TX.</p>]]></description>
      <pubDate>Fri, 08 Nov 2024 12:50 GMT</pubDate>
      <dc:identifier>2977589</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>BriaCell Therapeutics Corp.</dc:contributor>
      <dc:modified>Fri, 08 Nov 2024 12:51 GMT</dc:modified>
      <dc:subject>Calendar of Events</dc:subject>
      <dc:subject>Conference Calls/ Webcasts</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/11/04/2973985/0/en/BriaCell-Overall-Survival-Data-Selected-for-Spotlight-Poster-at-2024-San-Antonio-Breast-Cancer-Symposium-December-10-13.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/11/04/2973985/0/en/BriaCell-Overall-Survival-Data-Selected-for-Spotlight-Poster-at-2024-San-Antonio-Breast-Cancer-Symposium-December-10-13.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX:BCT</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:BCTXW</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:BCTX</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA10778Y1043</category>
      <title>BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium®, December 10 – 13</title>
      <description><![CDATA[<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, Nov.  04, 2024  (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces five posters, including a Spotlight poster presentation, at the San Antonio Breast Cancer Symposium<sup>®</sup> (SABCS<sup>®</sup>) 47th Annual Meeting, being held December 10 – 13 , 2024, at the Henry B. Gonzalez Convention Center, San Antonio, Texas.</p>]]></description>
      <pubDate>Mon, 04 Nov 2024 12:50 GMT</pubDate>
      <dc:identifier>2973985</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>BriaCell Therapeutics Corp.</dc:contributor>
      <dc:modified>Mon, 04 Nov 2024 12:51 GMT</dc:modified>
      <dc:subject>Calendar of Events</dc:subject>
      <dc:subject>Health</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/10/22/2966845/0/en/BriaCell-Reports-Outperforming-Metastatic-Breast-Cancer-Patients-and-Standard-Beating-Survival-Data.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/10/22/2966845/0/en/BriaCell-Reports-Outperforming-Metastatic-Breast-Cancer-Patients-and-Standard-Beating-Survival-Data.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX:BCT</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:BCTXW</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:BCTX</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA10778Y1043</category>
      <title>BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data</title>
      <description><![CDATA[<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, Oct.  22, 2024  (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces new positive survival data, outperforming patients, and survival rates in its Phase 2 metastatic breast cancer (MBC) study.</p>]]></description>
      <pubDate>Tue, 22 Oct 2024 11:50 GMT</pubDate>
      <dc:identifier>2966845</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>BriaCell Therapeutics Corp.</dc:contributor>
      <dc:modified>Tue, 22 Oct 2024 11:50 GMT</dc:modified>
      <dc:subject>Health</dc:subject>
      <dc:subject>Clinical Study</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/10/15/2963094/0/en/BriaCell-Provides-Phase-3-Clinical-Engagement-Update-in-Metastatic-Breast-Cancer-Pivotal-Study.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/10/15/2963094/0/en/BriaCell-Provides-Phase-3-Clinical-Engagement-Update-in-Metastatic-Breast-Cancer-Pivotal-Study.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX:BCT</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:BCTXW</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:BCTX</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA10778Y1043</category>
      <title>BriaCell Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Pivotal Study</title>
      <description><![CDATA[<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, Oct.  15, 2024  (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today provides a clinical engagement update of its pivotal Phase 3 study of Bria-IMT™ in combination with immune check point inhibitor in metastatic breast cancer (MBC). The study will enroll up to 354 patients randomized 1:1 to the BriaCell combination regimen or physician’s choice and will include a small number (n=50) of patients randomized to Bria-IMT™ monotherapy.</p>]]></description>
      <pubDate>Tue, 15 Oct 2024 11:50 GMT</pubDate>
      <dc:identifier>2963094</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>BriaCell Therapeutics Corp.</dc:contributor>
      <dc:modified>Tue, 15 Oct 2024 11:51 GMT</dc:modified>
      <dc:subject>Clinical Study</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/10/02/2957352/0/en/BriaCell-Therapeutics-Announces-Closing-of-5-Million-Offering.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/10/02/2957352/0/en/BriaCell-Therapeutics-Announces-Closing-of-5-Million-Offering.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX:BCT</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:BCTXW</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:BCTX</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA10778Y1043</category>
      <title>BriaCell Therapeutics Announces Closing of $5 Million Offering</title>
      <description><![CDATA[<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, Oct.  02, 2024  (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced best-efforts offering of 5,128,500 common shares and warrants to purchase up to 5,128,500 common shares at a combined offering price of $0.975 per share and associated warrant, priced at-the-market under Nasdaq rules. The warrants have an exercise price of $0.85 per share and are immediately exercisable upon issuance for a period of five years following the date of issuance. Total gross proceeds from the offering, before deducting the placement agent’s fees and other offering expenses, are approximately $5 million.<br></p>]]></description>
      <pubDate>Wed, 02 Oct 2024 20:05 GMT</pubDate>
      <dc:identifier>2957352</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>BriaCell Therapeutics Corp.</dc:contributor>
      <dc:modified>Wed, 02 Oct 2024 20:06 GMT</dc:modified>
      <dc:subject>Financing Agreements</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/10/01/2956516/0/en/BriaCell-Therapeutics-Announces-5-Million-Offering.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/10/01/2956516/0/en/BriaCell-Therapeutics-Announces-5-Million-Offering.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX:BCT</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:BCTXW</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:BCTX</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA10778Y1043</category>
      <title>BriaCell Therapeutics Announces $5 Million Offering</title>
      <description><![CDATA[Priced At-the-Market Under Nasdaq Rules <pre>Priced At-the-Market Under Nasdaq Rules</pre>]]></description>
      <pubDate>Tue, 01 Oct 2024 18:05 GMT</pubDate>
      <dc:identifier>2956516</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>BriaCell Therapeutics Corp.</dc:contributor>
      <dc:modified>Tue, 01 Oct 2024 18:05 GMT</dc:modified>
      <dc:subject>Health</dc:subject>
      <dc:subject>Changes in company's own shares</dc:subject>
      <dc:subject>Warrants and Certificates</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/10/01/2956018/0/en/BriaCell-Reports-100-Resolution-of-Brain-Metastasis-in-Breast-Cancer-Patient-with-Eye-Bulging-Tumor.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/10/01/2956018/0/en/BriaCell-Reports-100-Resolution-of-Brain-Metastasis-in-Breast-Cancer-Patient-with-Eye-Bulging-Tumor.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX:BCT</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:BCTXW</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:BCTX</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA10778Y1043</category>
      <title>BriaCell Reports 100% Resolution of Brain Metastasis in Breast Cancer Patient with “Eye-Bulging” Tumor</title>
      <description><![CDATA[<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, Oct.  01, 2024  (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to report dramatic anti-tumor response including complete resolution of temporal lobe breast cancer metastasis in a patient treated in the Phase 2 study of BriaCell’s Bria-IMT™ plus an immune checkpoint inhibitor regimen. The patient demonstrated an initial partial response at 2 months in the brain lesion with no detectable disease following 8 and 11 months of treatment.</p>]]></description>
      <pubDate>Tue, 01 Oct 2024 11:50 GMT</pubDate>
      <dc:identifier>2956018</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>BriaCell Therapeutics Corp.</dc:contributor>
      <dc:modified>Tue, 01 Oct 2024 11:50 GMT</dc:modified>
      <media:content
        medium="image"
        type="image/jpeg"
        width="600"
        url="https://ml.globenewswire.com/Resource/Download/0a328ad2-c48d-43bf-ae04-0b69da4d3f3f">
        <media:text
          type="html"><![CDATA[<p>
  <a href="https://www.globenewswire.com/news-release/2024/10/01/2956018/0/en/BriaCell-Reports-100-Resolution-of-Brain-Metastasis-in-Breast-Cancer-Patient-with-Eye-Bulging-Tumor.html">
    <img src="https://ml.globenewswire.com/Resource/Download/0a328ad2-c48d-43bf-ae04-0b69da4d3f3f" width="600" align="left" border="0" alt="Figure 1" title="Bria-IMT™ regimen resulted in 100% resolution of tumor in the right temporal lobe region of the brain" />
  </a>
</p><br clear="all" />]]></media:text>
        <media:credit
          role="publishing company">GlobeNewswire Inc.</media:credit>
      </media:content>
      <media:content
        medium="image"
        type="image/jpeg"
        width="600"
        url="https://ml.globenewswire.com/Resource/Download/eea9560e-c63a-4001-a5b7-6a07caf3c91b">
        <media:text
          type="html"><![CDATA[<p>
  <a href="https://www.globenewswire.com/news-release/2024/10/01/2956018/0/en/BriaCell-Reports-100-Resolution-of-Brain-Metastasis-in-Breast-Cancer-Patient-with-Eye-Bulging-Tumor.html">
    <img src="https://ml.globenewswire.com/Resource/Download/eea9560e-c63a-4001-a5b7-6a07caf3c91b" width="600" align="left" border="0" alt="Figure 2" title="Bria-IMT™ regimen resulted in near complete resolution of breast cancer tumor in the right orbit (behind the eye)" />
  </a>
</p><br clear="all" />]]></media:text>
        <media:credit
          role="publishing company">GlobeNewswire Inc.</media:credit>
      </media:content>
      <dc:subject>Product / Services Announcement</dc:subject>
      <dc:subject>Clinical Study</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/09/18/2948125/0/en/BriaCell-Announces-FDA-Authorized-Expanded-Access-Policy-for-Metastatic-Breast-Cancer-Patients.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/09/18/2948125/0/en/BriaCell-Announces-FDA-Authorized-Expanded-Access-Policy-for-Metastatic-Breast-Cancer-Patients.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX:BCT</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:BCTXW</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:BCTX</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA10778Y1043</category>
      <title>BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients</title>
      <description><![CDATA[<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, Sept.  18, 2024  (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce U.S. FDA (FDA) authorization of an Expanded Access Policy (EAP) for metastatic breast cancer (MBC) patients.</p>]]></description>
      <pubDate>Wed, 18 Sep 2024 11:50 GMT</pubDate>
      <dc:identifier>2948125</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>BriaCell Therapeutics Corp.</dc:contributor>
      <dc:modified>Wed, 18 Sep 2024 11:50 GMT</dc:modified>
      <dc:subject>Health</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/09/12/2945578/0/en/BriaCell-Therapeutics-Announces-Closing-of-8-5-Million-Offering.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/09/12/2945578/0/en/BriaCell-Therapeutics-Announces-Closing-of-8-5-Million-Offering.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX:BCT</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:BCTXW</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:BCTX</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA10778Y1043</category>
      <title>BriaCell Therapeutics Announces Closing of $8.5 Million Offering</title>
      <description><![CDATA[<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, Sept.  12, 2024  (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced best-efforts offering priced at-the-market under Nasdaq rules for 12,325,000 common shares. Each common share was sold at an offering price of $0.69 per share, for gross proceeds of approximately $8.5 million, before deducting placement agent fees and other offering expenses. All the shares in the offering were offered by the Company.<br></p>]]></description>
      <pubDate>Thu, 12 Sep 2024 20:05 GMT</pubDate>
      <dc:identifier>2945578</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>BriaCell Therapeutics Corp.</dc:contributor>
      <dc:modified>Thu, 12 Sep 2024 20:05 GMT</dc:modified>
      <dc:subject>Changes in company's own shares</dc:subject>
      <dc:subject>Major shareholder announcements</dc:subject>
      <dc:subject>Prospectus/Announcement of Prospectus</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/09/11/2944684/0/en/BriaCell-Therapeutics-Announces-8-5-Million-Offering.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/09/11/2944684/0/en/BriaCell-Therapeutics-Announces-8-5-Million-Offering.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX:BCT</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:BCTXW</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:BCTX</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA10778Y1043</category>
      <title>BriaCell Therapeutics Announces $8.5 Million Offering</title>
      <description><![CDATA[Priced At-the-Market Under Nasdaq Rules <pre>Priced At-the-Market Under Nasdaq Rules</pre>]]></description>
      <pubDate>Wed, 11 Sep 2024 16:09 GMT</pubDate>
      <dc:identifier>2944684</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>BriaCell Therapeutics Corp.</dc:contributor>
      <dc:modified>Wed, 11 Sep 2024 16:10 GMT</dc:modified>
      <dc:subject>Health</dc:subject>
      <dc:subject>Changes in company's own shares</dc:subject>
      <dc:subject>Major shareholder announcements</dc:subject>
      <dc:subject>Prospectus/Announcement of Prospectus</dc:subject>
      <dc:subject>Warrants and Certificates</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/09/11/2944400/0/en/BriaCell-Reports-Positive-Overall-Survival-OS-in-Metastatic-Breast-Cancer.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/09/11/2944400/0/en/BriaCell-Reports-Positive-Overall-Survival-OS-in-Metastatic-Breast-Cancer.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX:BCT</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:BCTXW</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:BCTX</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA10778Y1043</category>
      <title>BriaCell Reports Positive Overall Survival (OS) in Metastatic Breast Cancer</title>
      <description><![CDATA[<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, Sept.  11, 2024  (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce positive overall survival data of its Phase 2 clinical study of Bria-IMT™ in combination with an immune check point inhibitor (CPI) in late stage metastatic breast cancer.</p>]]></description>
      <pubDate>Wed, 11 Sep 2024 11:50 GMT</pubDate>
      <dc:identifier>2944400</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>BriaCell Therapeutics Corp.</dc:contributor>
      <dc:modified>Wed, 11 Sep 2024 11:50 GMT</dc:modified>
      <dc:subject>Health</dc:subject>
      <dc:subject>Clinical Study</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/09/10/2943571/0/en/BriaCell-Announces-Positive-Pre-IND-Meeting-with-FDA-for-Bria-PROS-for-Prostate-Cancer.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/09/10/2943571/0/en/BriaCell-Announces-Positive-Pre-IND-Meeting-with-FDA-for-Bria-PROS-for-Prostate-Cancer.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX:BCT</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:BCTXW</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:BCTX</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA10778Y1043</category>
      <title>BriaCell Announces Positive Pre-IND Meeting with FDA for Bria-PROS+™ for Prostate Cancer</title>
      <description><![CDATA[<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, Sept.  10, 2024  (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that it has received positive feedback from its Pre-IND meeting with the U.S. Food and Drug Administration (FDA), which is a step forward to opening an IND to conduct a Phase 1/2 study of its personalized off-the-shelf immunotherapy, Bria-PROS+™, in advanced prostate cancer.</p>]]></description>
      <pubDate>Tue, 10 Sep 2024 11:50 GMT</pubDate>
      <dc:identifier>2943571</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>BriaCell Therapeutics Corp.</dc:contributor>
      <dc:modified>Tue, 10 Sep 2024 11:51 GMT</dc:modified>
      <dc:subject>Clinical Study</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/09/09/2942742/0/en/BriaCell-Announces-Presentation-at-the-2024-Society-for-Immunotherapy-of-Cancer-SITC-Annual-Meeting.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/09/09/2942742/0/en/BriaCell-Announces-Presentation-at-the-2024-Society-for-Immunotherapy-of-Cancer-SITC-Annual-Meeting.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX:BCT</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:BCTXW</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:BCTX</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA10778Y1043</category>
      <title>BriaCell Announces Presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting</title>
      <description><![CDATA[<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, Sept.  09, 2024  (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces a poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, held November 6-10, 2024, in Houston, TX.<br></p>]]></description>
      <pubDate>Mon, 09 Sep 2024 11:50 GMT</pubDate>
      <dc:identifier>2942742</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>BriaCell Therapeutics Corp.</dc:contributor>
      <dc:modified>Mon, 09 Sep 2024 11:50 GMT</dc:modified>
      <dc:subject>Calendar of Events</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/07/18/2915201/0/en/BriaCell-Quadruples-Progression-Free-Survival-PFS-in-Patient-with-Eye-Bulging-Metastatic-Breast-Cancer.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/07/18/2915201/0/en/BriaCell-Quadruples-Progression-Free-Survival-PFS-in-Patient-with-Eye-Bulging-Metastatic-Breast-Cancer.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX:BCT</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:BCTXW</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:BCTX</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA10778Y1043</category>
      <title>BriaCell Quadruples Progression Free Survival (PFS) in Patient with “Eye-Bulging” Metastatic Breast Cancer</title>
      <description><![CDATA[<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, July  18, 2024  (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to report significantly higher PFS for its top responder patient in the Phase 2 study of BriaCell’s Bria-IMT™ regimen in combination with an immune checkpoint inhibitor in metastatic breast cancer. The patient remains alive and she continues to receive BriaCell’s treatment regimen.</p>]]></description>
      <pubDate>Thu, 18 Jul 2024 11:56 GMT</pubDate>
      <dc:identifier>2915201</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>BriaCell Therapeutics Corp.</dc:contributor>
      <dc:modified>Thu, 18 Jul 2024 11:57 GMT</dc:modified>
      <media:content
        medium="image"
        type="image/jpeg"
        width="600"
        url="https://ml.globenewswire.com/Resource/Download/cef51e5b-ff25-4c3e-929d-22ad6df22927">
        <media:text
          type="html"><![CDATA[<p>
  <a href="https://www.globenewswire.com/news-release/2024/07/18/2915201/0/en/BriaCell-Quadruples-Progression-Free-Survival-PFS-in-Patient-with-Eye-Bulging-Metastatic-Breast-Cancer.html">
    <img src="https://ml.globenewswire.com/Resource/Download/cef51e5b-ff25-4c3e-929d-22ad6df22927" width="600" align="left" border="0" alt="Figure 1: Responder Images - Bria-IMT™ Regimen" title="Figure 1: Responder Images - Bria-IMT™ Regimen" />
  </a>
</p><br clear="all" />]]></media:text>
        <media:credit
          role="publishing company">GlobeNewswire Inc.</media:credit>
      </media:content>
      <dc:subject>Clinical Study</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/06/03/2892215/0/en/BriaCell-Presents-Clinical-Efficacy-Data-at-ASCO-2024.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/06/03/2892215/0/en/BriaCell-Presents-Clinical-Efficacy-Data-at-ASCO-2024.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX:BCT</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:BCTXW</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:BCTX</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA10778Y1043</category>
      <title>BriaCell Presents Clinical Efficacy Data at ASCO 2024</title>
      <description><![CDATA[<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, June  03, 2024  (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces positive clinical efficacy data updates of its ongoing randomized Phase 2 study evaluating lead clinical candidate Bria-IMT™ in patients with advanced metastatic breast cancer. Two poster sessions, one abstract, and one oral presentation session (by Principal Investigator and Professor of Oncology, Mayo Clinic, Saranya Chumsri, MD), will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place today June 3, 2024 at McCormick Place, Chicago, IL.<br></p>]]></description>
      <pubDate>Mon, 03 Jun 2024 12:00 GMT</pubDate>
      <dc:identifier>2892215</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>BriaCell Therapeutics Corp.</dc:contributor>
      <dc:modified>Mon, 03 Jun 2024 12:01 GMT</dc:modified>
      <media:content
        medium="image"
        type="image/jpeg"
        width="600"
        url="https://ml.globenewswire.com/Resource/Download/6fff10ca-4660-4c6f-bb46-719f0f21887d">
        <media:text
          type="html"><![CDATA[<p>
  <a href="https://www.globenewswire.com/news-release/2024/06/03/2892215/0/en/BriaCell-Presents-Clinical-Efficacy-Data-at-ASCO-2024.html">
    <img src="https://ml.globenewswire.com/Resource/Download/6fff10ca-4660-4c6f-bb46-719f0f21887d" width="600" align="left" border="0" alt="Figure 1" title="Effect of treatment sequence and formulation on PFS" />
  </a>
</p><br clear="all" />]]></media:text>
        <media:credit
          role="publishing company">GlobeNewswire Inc.</media:credit>
      </media:content>
      <media:content
        medium="image"
        type="image/jpeg"
        width="600"
        url="https://ml.globenewswire.com/Resource/Download/2b7cbddb-da76-486d-b6c3-22894a42933a">
        <media:text
          type="html"><![CDATA[<p>
  <a href="https://www.globenewswire.com/news-release/2024/06/03/2892215/0/en/BriaCell-Presents-Clinical-Efficacy-Data-at-ASCO-2024.html">
    <img src="https://ml.globenewswire.com/Resource/Download/2b7cbddb-da76-486d-b6c3-22894a42933a" width="600" align="left" border="0" alt="Figure 2" title="Objective Response Rate (ORR) and Clinical Benefit Rate (CBR) in the Bria-IMT™ Phase 1/2 Study" />
  </a>
</p><br clear="all" />]]></media:text>
        <media:credit
          role="publishing company">GlobeNewswire Inc.</media:credit>
      </media:content>
      <media:content
        medium="image"
        type="image/jpeg"
        width="600"
        url="https://ml.globenewswire.com/Resource/Download/66f03119-a4b3-4d2d-a998-ab355aefdeac">
        <media:text
          type="html"><![CDATA[<p>
  <a href="https://www.globenewswire.com/news-release/2024/06/03/2892215/0/en/BriaCell-Presents-Clinical-Efficacy-Data-at-ASCO-2024.html">
    <img src="https://ml.globenewswire.com/Resource/Download/66f03119-a4b3-4d2d-a998-ab355aefdeac" width="600" align="left" border="0" alt="Figure 3" title="Intracranial Tumor Responses in Patients with Intracranial Metastases Treated with Bria-IMT™" />
  </a>
</p><br clear="all" />]]></media:text>
        <media:credit
          role="publishing company">GlobeNewswire Inc.</media:credit>
      </media:content>
      <dc:subject>Clinical Study</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/05/30/2890719/0/en/BriaCell-Initiates-Patient-Enrollment-in-First-in-Human-Study-of-Bria-OTS-in-Advanced-Metastatic-Breast-Cancer.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/05/30/2890719/0/en/BriaCell-Initiates-Patient-Enrollment-in-First-in-Human-Study-of-Bria-OTS-in-Advanced-Metastatic-Breast-Cancer.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX:BCT</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:BCTXW</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:BCTX</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA10778Y1043</category>
      <title>BriaCell Initiates Patient Enrollment in First-in-Human Study of Bria-OTS™ in Advanced Metastatic Breast Cancer</title>
      <description><![CDATA[<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May  30, 2024  (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces initiation of a first-in-human, Phase 1/2 study evaluating safety and efficacy of Bria-OTS™, BriaCell’s personalized off-the-shelf next generation immunotherapy, as monotherapy and <a href="https://www.globenewswire.com/Tracker?data=R9NTVLP8gqjGecm6JQemdC-my2ZpapRSLQt8j_uWmry7MepSCWMDPEglZtRzgN130EKwlFGsHYhBg4DJL7qroh_32bvGBCLmbPilzSV7vs9o7vmBM-3EUo0Wv-GC4Ah6qYKRzaFUUrf34q4Pq8-aTItMSt80VyQHUCsDVpjcRGCL75AKeqAI8IMlVM8q-_LW" rel="nofollow" target="_blank" title="in combination with PD-1 inhibitor tislelizumab">in combination with PD-1 inhibitor tislelizumab</a>, in advanced metastatic breast cancer.<br></p>]]></description>
      <pubDate>Thu, 30 May 2024 12:00 GMT</pubDate>
      <dc:identifier>2890719</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>BriaCell Therapeutics Corp.</dc:contributor>
      <dc:modified>Thu, 30 May 2024 12:01 GMT</dc:modified>
      <dc:subject>Company Announcement</dc:subject>
    </item>
  </channel>
</rss>